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ABSTRACT 
Phenytoin is a narrow therapeutic indexed antiepileptic drug. Many drugs competitively inhibit isoenzymes responsible for its metabolism when 
concurrently administered and increases the phenytoin plasma concentration leading to serious adverse effects. One such case is being reported 
with phenytoin toxicity due to concurrent administration of phenytoin and Isoniazid 
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INTRODUCTION 
Phenytoin is one of the most commonly used antiepileptic 
medications in clinical practice for generalized seizures.[1] It is 
known to cause a range of deleterious and erratic side effects, 
reported previously including nystagmus, ataxia, facial puffiness, 
urinary incontinence, enlargement of lips, hepatitis, rash and 
vomiting.[2,3] Drug interactions may alter phenytoin concentrations 
in plasma and become clinically very significant due to its narrow 
therapeutic index. The risk of Phenytoin toxicity increases among 
the patients concurrently receiving Isoniazid, due to impaired 
phenytoin metabolism by Isoniazid with an increased incidence up 
to 19%[4] 
CASE REPORT 
A 21 year old male patient belonging to the middle socio-economic 
status presented to the neurology outpatient department with 
complaints of decreased urine output, enlargement of lips, facial 
puffiness, vomiting, generalized body rashes, blurring of vision and 
unsteadiness of gait since 2 days. 
His past medical history revealed that he was diagnosed with 
tubercular meningitis and generalized tonic clinics seizures for 
which he was hospitalized 3 weeks earlier. He had received 
Tab.Phenytoin 300 mg per day in divided doses and anti tubercular 
drugs (Isoniazid 300 mg, Rifampicin 450 mg, Pyrazinamide 1500 mg, 
Ethambutol 800 mg) once daily. After 3 months, the patient 
presented to the neurology department with complaints of blurring 
of vision, difficulty in walking, unsteadiness, generalized macular 
rashes over limbs, chest and back, vomiting, urinary incontinence 
and decreased urinary output. MRI scan of the brain and spinal cord 
did not reveal any organic/structural lesions. USG of abdomen 
including the KUB region was normal. Liver function tests showed a 
fourfold elevation in amino transferase levels. Other biochemical 
parameters were normal. 
A provisional diagnosis was made of phenytoin toxicity and he was 
admitted to the hospital. Based on the clinical findings and other 
evidences, phenytoin and all anti tubercular medications were 
dechallenged and the patient was started on T. Levetiracetam 500 
mg per day for epilepsy, Ondansetron 4 mg for vomiting, Fusidic acid 
cream for rash, Ursodeoxycholic acid 300 mg for hepatitis. 
Phenytoin assay showed that his serum Phenytoin levels were found 
to be > 40 mcg/ml (reference range: 15-20 mcg/ml). 
Ophthalmological examination revealed gaze included horizontal 
Nystagmus. After 2 weeks of hospitalization and withdrawal of 
Phenytoin and ATT, the patient showed a dramatic improvement in 
symptoms including the visual blurring episode, ataxia, vomiting, 
enlargement of lips, urinary incontinence and rash. 
Aminotransferase levels were also found normal in subsequent liver 
function tests. 
 
DISCUSSION 
Phenytoin is one of the most widely-prescribed antiepileptic drugs 
in clinical practice for the management of generalised tonic clonic 
seizures and complex partial seizures. It may also be used in the 
prevention of seizures following head trauma, and in ventricular 
arrhythmias. The absorption of phenytoin varies with dosage form 
and in the salt form absorption is rapid and more than 90%. It is 
highly protein bound and extensively metabolised by hepatic 
microsomal isoenzymes CYP2C9 and CYP2C19. Phenytoin follows 
zero order kinetics at therapeutic concentrations, because the rate of 
metabolism is close to the maximum capacity of the enzyme 
involved. Clinically effective serum level is usually 10–20 mcg/mL. 
With recommended dosage, a period of seven to ten days is adequate 
to achieve steady-state plasma concentration of phenytoin. When 
phenytoin is co-administered with Isoniazid, the serum 
concentration levels of phenytoin will significantly increase due to 
competitive inhibition of CYP2C19 by Isoniazid. A report from 
previous study suggests that consequences of drug interaction are 
manifested between 5-22 days.4 In this patient, phenytoin toxicity 
was observed after 11 weeks. Investigations were carried out to 
exclude any structural organic cause for the clinical manifestations 
and found all negative. The symptoms experienced by the patient in 
question are understandable in terms of complex pharmacokinetics, 
narrow therapeutic index and individual variability in metabolism 
and elimination of phenytoin. This patient developed exaggerated 
side effects gradually over a period of 3 months after the 
concomitant use of phenytoin with Isoniazid, which can be explained 
by gradual elevation of the drug in the plasma over the time as the 
pharmacokinetic of the phenytoin follows ranging from 1st order 
kinetic to Zero order kinetic, hence even minor dosage changes can 
result in variable concentration as the elimination is saturated. 
CONCLUSION 
This case report serves as an alert to clinicians to remain clinically 
vigilant for such manifestations in patients when phenytoin and 
Isoniazid are concomitantly administered. While prescribing 
Isoniazid and phenytoin, a caution on dosage adjustment of 
phenytoin is advisable. Since specific guidelines for adjustment of 
dosage are not established, it is recommended that the required 
dosage of phenytoin in such situations be guided by the clinical 
symptoms as well as frequent neurological evaluation serum assay 
of phenytoin when ever indicated. 
REFERENCES 
1. Livanainen M, Savolainen H. Side effects of phenobarbitol and 
phenytoin during long term treatment of epilepsy. Acta Neurol 
Scand Suppl 1983; 97:49-67. 
 Vol 7, Issue 2, 2014                                                                                                                                                                                                              ISSN - 0974-2441                                                                                                                                                                                                 
SOUMYA REDDY1, SARAYU P1, SRIKANTH M.S1, RAMESH ADEPU1*, KESHAVA B.S2 
Ramesh et al. 
Asian J Pharm Clin Res, Vol 7, Suppl 1, 2014, 1-2 
222 
 
2. Larsen JR, Larsen LS. Clinical features and management of 
poisoning due to phenytoin. Med Toxicol Adverse Drug Exp 
1989;4(4):229-45. 
3. Roger L. Nation. Pharmacokinetic Drug Interaction with 
Phenytoin (part 1). Clin.Pharmacokinet. 18 (1):37-60,1990. 
4. Russell R. Miller, J Porter, D J Greenblatt. Clinical importance of 
Interaction of Phenytoin and Isoniazid: A report from the 
Boston collaborative drug Survillance Program. CHEST 
1979;75(3):356-358. 
5. Zeruesenay Desta, Nadia V Soukhova, David A Flockhart. 
Inhibition of cytochrome P450 (Cyp450) isoforms by Isoniazid: 
potent inhibition of Cyp2C19 & Cyp3A. Antimicrob agents 
Chemother. 2001; 45(2): 382-392. 
6. Hussein A, Abdulgalil A, Omer F, Eltoum H, Hamad A, El-Adil O, 
et al. correlation between serum level of antiepileptic drugs 
and their Side Effects. Oman Med J 2010; 25(1): 17-21. 
 
 
